What is the fair value of Novartis AG ADR (NYSE-NVS) stock?

The current fair value estimate for Novartis AG ADR (NYSE-NVS) is $159.58. This implies an estimated upside of 5.6% versus the current market price.

Is Novartis AG ADR (NYSE-NVS) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 5.6% versus the current market price.

What is the analyst price target for NYSE-NVS stock?

The available analyst price target for Novartis AG ADR (NYSE-NVS) is $154.65. The analyst target implies estimated upside of 2.3%.

How is the financial health of Novartis AG ADR?

The current financial health read for Novartis AG ADR (NYSE-NVS) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

Does Novartis AG ADR (NYSE-NVS) pay dividends?

Based on the current data, dividend yield is 2.0%.

What is the P/E ratio for Novartis AG ADR (NYSE-NVS)?

The current P/E ratio listed for Novartis AG ADR (NYSE-NVS) is 23.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Novartis AG ADR?

The current market capitalization listed for Novartis AG ADR is 294.8 B.

What is the enterprise value of Novartis AG ADR?

The current enterprise value listed for Novartis AG ADR is 335.8 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Novartis AG ADR?

The ticker symbol for Novartis AG ADR is NYSE-NVS, and the stock is listed on NYSE.

Where is Novartis AG ADR (NYSE-NVS) listed?

Novartis AG ADR (NYSE-NVS) is listed on NYSE.

What is the debt-to-total-capital ratio for Novartis AG ADR?

The current debt-to-total-capital ratio listed for Novartis AG ADR is 14.1%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Novartis AG ADR?

The free float listed for Novartis AG ADR is 97.7%. Free float helps investors understand how much of the share base is available for public trading.

Novartis AG ADR (NVS) Fair Value & Stock Analysis

Novartis AG ADR (NVS)

Novartis AG ADR is a depositary receipt representing common stock of Novartis AG, a Switzerland-based global pharmaceutical company listed on the NYSE under the ticker NVS. Through its underlying issuer, the business researches, develops, manufactures, markets, and sells medicines in Switzerland and international markets. Its portfolio includes treatments across cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. Key products named in the source include Entresto, Cosentyx, Kisqali, Promacta/Revolade, Tafinlar plus Mekinist, Jakavi, Tasigna, Xolair, Ilaris, Pluvicto, Sandostatin SC and Sandostatin LAR, Zolgensma, Lucentis, Leqvio, Lutathera, Scemblix, and Fabhalta. Novartis was incorporated in 1996 and is headquartered in Basel, Switzerland.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NYSE-NVS	$159.58	5.6% Upside	Fair	$154.65	2.3% Upside	Fair	Great	2.0%	23.1x	7.1x	5.2x	294.8 B	335.8 B	14.1%	97.7%	8.0	71.1%	131.4%